Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track.

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Disclosed in the fine print of the pharma giant's fourth-quarter earnings presentation Tuesday was that two more studies are subject to the hold, bringing the total number of affected trials to seven. [ABSTRACT FROM AUTHOR]